A leading contributor of science and knowledge through discoveries.

 
← Back to Profiles

Daniel Sitar BScPharm, MSc, PhD, FCP

Currently Not Accepting Students.

Current Position

Professor Emeritus

History

1972 PhD Pharmacology (major), Physiology (minor), University of Manitoba
1968 MSc Pharmacy (major), Chemistry (minor), University of Manitoba
1966 BScPharm Pharmaceutical Chemistry (major), University of Manitoba

Research Focus:

The Clinical Pharmacology Section has a long-term interest in issues related to optimization of drug therapy of diseases. Many drugs used to treat childhood diseases have never been studied in pediatric patients. My own research focus relates to mechanisms of drug elimination, and their alteration as a result of development and disease processes. One study area includes control of excretion of basic drugs by the kidney. Studies in animals and humans, and studies with animal and human kidney tissue are being completed to define diseases where renal tubular transport is altered. An initial focus is on the effects of early diabetes on drug elimination by the kidney. Another research area is the determination of novel conjugation mechanisms in drug metabolism, and their potential application as diagnostic tools. We have recently demonstrated that amantadine acetylation is mediated solely by spermidine/spermine N1-acetyltransferase. The specificity of this reaction has implications for the diagnosis of cancer. Our laboratory is involved also in collaborative research related to the discovery of new therapeutic targets, and the optimization of drug therapy. Many of these studies are using pharmacokinetic and pharmacodynamic modeling as tools to determine the potential for drug dose optimization in relevant patient populations. All of these research projects involve analytical methods by high performance liquid chromatography, gas liquid chromatography and radioactive isotope tracer techniques. Data analyses include pharmacokinetic modelling and classic enzyme kinetic approaches. Finally, we continue our studies in clinical toxicology that are directed at determining effective regimens for gastrointestinal tract decontamination after patient presentation to the hospital with a drug overdose.